HIGHLIGHTS
- who: Jia Wang from the Harvard Medical School, United States Medical University of Lublin, Poland have published the Article: Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial, in the Journal: (JOURNAL)
- what: This study compared the status of PB lymphocyte and CD4+ T_cell subsets of refractory RA with healthy donors. Subcutaneous injection of IL-2 combined with traditional antirheumatic drugs Therefore, the authors propose an immunoregulation therapy to induce and reconstitute immune tolerance by low-dose IL-2 subcutaneous injection . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.